目的 探讨丹红注射液联合去乙酰毛花苷注射液治疗急性左心衰竭的临床疗效。方法 选取2022年4月—2025年3月长治医学院附属和平医院收治的76例急性左心衰竭患者，全部患者以随机数字表法分为对照组和治疗组，各38例。对照组滴注去乙酰毛花苷注射液，首次1支加入300 mL葡萄糖注射液，4 h加入1支直至症状完全缓解。治疗组在对照组基础上滴注丹红注射液，每次2支加入300 mL葡萄糖注射液，2次/d。两组治疗2 d。比较两组患者的临床疗效、血流动力学、心功能指标、血清指标。结果 治疗组的总有效率为94.74%，对照组的总有效率为78.95%，两组组间比较差异有统计学意义（P＜0.05）。治疗后两组的心率（HR）、平均动脉压（MAP）、体循环阻力（SVR）、平均肺动脉压（MPAP）均显著减小（P＜0.05），治疗组的HR、MAP、SVR、MPAP低于对照组（P＜0.05）。两组治疗后的左心室射血分数（LVEF）、每搏输出量（SV）、心输出量（CO）显著升高（P＜0.05）；治疗组治疗后的LVEF、SV、CO均高于对照组（P＜0.05）。两组治疗后的血清可溶性致癌抑制因子2（sST2）、分泌型卷曲相关蛋白5（sFRP5）、肌酸激酶同工酶（CK-MB）水平显著降低（P＜0.05）；治疗组的血清sST2、sFRP5、CK-MB水平低于对照组（P＜0.05）。结论 丹红注射液联合去乙酰毛花苷注射液可提高急性左心衰竭的疗效，进一步改善血流动力学，提高心功能，减轻心肌炎性损伤。

Objective To investigate the clinical efficacy of Danhong Injection combined with Deslanoside Injection in treatment of acute left heart failure. Methods Seventy-six patients with acute left heart failure admitted to Heping Hospital Affiliated to Changzhi Medical University from April 2022 to March 2025 were selected. All patients were divided into control group and treatment group according to the random number table method, with 38 cases in each group. The control group received iv infusion of Deslanoside Injection, with one dose added to 300 mL glucose injection for the first time. After four hours, one dose was added until the symptoms were completely relieved. On the basis of treatment in the control group, the treatment group received iv infusion of Danhong Injection, 2 tubes/time, added to 300 mL glucose injection, twice daily. The two groups of patients were treated continuously for two days. Clinical efficacy, hemodynamic parameters, cardiac function indicators, and serum markers were compared between two groups. Results The total effective rate of the treatment group was 94.74%, while the total effective rate of the control group was 78.95%, and the difference between two groups was statistically significant (P < 0.05). After treatment, the heart rate (HR), mean arterial pressure (MAP), systemic vascular resistance (SVR), and mean pulmonary artery pressure (MPAP) of two groups were significantly reduced (P < 0.05). The HR, MAP, SVR, and MPAP of the treatment group were lower than those of the control group (P < 0.05). After treatment, the left ventricular ejection fraction (LVEF), stroke volume (SV), and cardiac output (CO) of two groups significantly increased (P < 0.05). The LVEF, SV, and CO of the treatment group were higher than those of the control group (P < 0.05). After treatment, the serum levels of soluble tumor suppressor 2 (sST2), secretory curl associated protein 5 (sFRP5), and creatine kinase isoenzyme (CK-MB) in two groups were significantly reduced (P < 0.05). The serum levels of sST2, sFRP5, and CK-MB in the treatment group were lower than those in the control group (P < 0.05). Conclusion Danhong Injection combined with Deslanoside Injection can improve the clinical efficacy of acute left heart failure, further improve hemodynamics, enhance cardiac function, and alleviate myocarditis injury.

R972

河北省中医药管理局项目（2021381）